check_circleStudy Completed

Bayer Identifier:

10954

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

EU CT Number:

Not Available
Dose-escalating Phase I study to define the safety profile, pharmacokinetics, pharmacodynamics and tumor response profile of BAY 43-9006 in combination with oxaliplatin chemotherapy in patients

Trial purpose

Key Participants Requirements

Sex

N/A

Age

32 - 79 Years
  • -

  • -

Trial summary

Enrollment Goal
37
Trial Dates
November 2002 - December 2007
Phase
Phase 1
Could I Receive a placebo
N/A
Products
Nexavar (Sorafenib, BAY43-9006)
Accepts Healthy Volunteer
No

Trial design

Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.Click here and search for websynopsis results provided by Bayer